ABUS insider trading
NasdaqGS HealthcareArbutus Biopharma Corp: insider trade history from SEC Form 4 filings.
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Company website: www.arbutusbio.com
ABUS insider activity at a glance
FilingIQ tracks 59 insider transactions for ABUS in filings since Aug 26, 2015. The most recent transaction is dated Sep 18, 2026.
Across the full history, 1 open-market purchases
and 24 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ABUS insider trades is 56.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ABUS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ABUS?
- FilingIQ tracks 59 Form 4 insider transactions for ABUS (Arbutus Biopharma Corp), covering filings from Aug 26, 2015 onwards. 12 of those are dated within the last 90 days.
- Are ABUS insiders net buyers or net sellers?
- Across the full Form 4 history for ABUS, 1 transactions (2%) were open-market purchases and 24 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ABUS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ABUS in?
- Arbutus Biopharma Corp (ABUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $857.77M.
Methodology & sources
Every ABUS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.